PAM
SVA

Panagora Asset Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Panagora Asset Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-25,805
Closed -$174K – 2688
2017
Q2 		$174K Sell
25,805
-16,532
-39% -$90.6K ﹤0.01% 1713
2017
Q1 		$243K Hold
42,337
– – ﹤0.01% 1597
2016
Q4 		$250K Hold
42,337
– – ﹤0.01% 1672
2016
Q3 		$250K Sell
42,337
-479
-1% -$2.82K ﹤0.01% 1689
2016
Q2 		$254K Buy
42,816
+1,929
+5% +$11.8K ﹤0.01% 1587
2016
Q1 		$261K Buy
+40,887
New +$245K ﹤0.01% 1569

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Panagora Asset Management's SVA Position: Q3 2017 in Review

Panagora Asset Management sold out of Sinovac Biotech, Ltd (SVA) in Q3 2017, closing a stake of 25,805 shares — an estimated $174K sold.

Panagora Asset Management first reported a position in SVA in Q1 2016 and held it in 6 quarters. The position peaked at $261K in Q1 2016. 35 funds tracked by Wall St. Rank hold SVA as of Q3 2017.

  • Panagora Asset Management reported no remaining Sinovac Biotech, Ltd position as of Q3 2017 after selling out during the quarter.
  • Panagora Asset Management sold 25,805 Sinovac Biotech, Ltd shares in Q3 2017, an estimated $174K.
  • Panagora Asset Management first reported a position in Sinovac Biotech, Ltd in Q1 2016 and held it in 6 quarters.
  • Panagora Asset Management's Sinovac Biotech, Ltd position peaked at $261K in Q1 2016.
  • 35 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2017.

Based on Panagora Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.